SUPERSEDED Local Coverage Determination (LCD)

Botulinum Toxins

L33949

Expand All | Collapse All
Proposed LCD
Proposed LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Proposed LCDs are not necessarily a reflection of the current policies or practices of the contractor.
Superseded
To see the currently-in-effect version of this document, go to the section.

Document Note

Note History

Contractor Information

LCD Information

Document Information

Source LCD ID
N/A
LCD ID
L33949
Original ICD-9 LCD ID
Not Applicable
LCD Title
Botulinum Toxins
Proposed LCD in Comment Period
N/A
Source Proposed LCD
N/A
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 12/01/2022
Revision Ending Date
12/06/2023
Retirement Date
N/A
Notice Period Start Date
N/A
Notice Period End Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

No changes were made.

Issue - Explanation of Change Between Proposed LCD and Final LCD

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1862(a)(10) excludes coverage for cosmetic surgery.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Code of Federal Regulations:

42 CFR Section 410.32 indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements)who furnishes a consultation or treats a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Tests not ordered by the physician (or other qualified non-physician provider) who is treating the beneficiary are not reasonable and necessary (see Sec. 411.15(k)(1) of this chapter).

CMS Publications:

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 8:

    50.5 Drugs and Biologicals [Coverage of SNF services]

 

    70 Medical and Other Health Services Furnished to SNF Patients.


CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 12:

    40.10 Drugs and Biologicals [Coverage of Comprehensive Outpatient Rehabilitation Facility services]


CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15:

    50.1–50.5 Drugs and Biologicals 120 Ambulatory Surgical Center Services


CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 16:

    260 Non-coverage for Cosmetic Procedures


CMS Publication 100-04; Medicare Claims Processing Manual, Chapter 17:

    40 Discarded Drugs and Biologicals


CMS Publication 100-04; Medicare Claims Processing Manual, Chapter 30:

    20.2.1 Categorical Denials

 

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Abstract:

Botulinum toxins are potent neuromuscular blocking agents that are useful in treating various focal muscle spastic disorders and excessive muscle contractions, such as dystonias, spasms, and twitches. They produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings. Since the resulting chemical denervation of muscle produces local paresis or paralysis, selected muscles can be treated. The clinical indications for botulinum toxins have increased exponentially since first used two decades ago. They are used in the treatment of overactive skeletal muscles (e.g. hemifacial spasm, dystonia, spasticity), smooth muscles (e.g. detrusor overactivity and achalasia), glands (e.g. sialorrhoea and hyperhidrosis) and additional conditions that are being investigated.

There are currently four botulinum toxin products commercially available in the United States: Botox® (onabotulinumtoxinA), Myobloc® (rimabotulinumtoxinB), Dysport™ (abobotulinumtoxinA), and Xeomin® (incobotulinumtoxinA). Each preparation has distinct pharmacological and clinical profiles specified on the product insert. Dosing patterns are also specific to the preparation of neurotoxin and are very different between different serotypes. Failure to recognize the unique characteristics of each formulation of botulinum toxin can lead to undesired patient outcomes. It is expected that physicians will be familiar with and experienced in the use of these agents, and utilize evidence-based medicine to select the appropriate drug and dose regimen for each patient condition. Physicians may decide which agent to use in beneficiary care except as noted below. Although botulinum toxins have only been FDA-approved for limited uses, they are frequently used off-label as well. A patient who is not responsive or who ceases to respond to one serotype may respond to the other.

This local coverage determination provides CGS’ indications and limitations of coverage for these pharmaceutical products.

Indications:

Spasticity

Botulinum toxin can be used to reduce spasticity or excessive muscular contractions, to relieve pain, to assist with posture and walking, to improve range of motion, to enhance the effectiveness of physical therapy, and to reduce severe spasm to allow better perineal hygiene.

Organic writer’s cramp is uncommon, and so botulinum toxin for the treatment of organic writer’s cramp should be infrequent.

Botulinum toxin is indicated for disorders associated with spastic conditions and dystonia. The wide range of botulinum toxin dosages used in a treatment session is determined by patient age, degree of spasticity, number of injections made into each muscle and number of muscles treated.

Electromyography or muscle stimulation, rather than site pain or tenderness, to determine injection site(s) for botulinum toxin may be necessary, especially for spastic conditions of the face, neck, and hand.

Blepharospasm

Botulinum toxin injection therapy is accepted first line treatment for patients with blepharospasm and/or hemifacial spasm. If the upper and lower lid of the same eye and/or adjacent facial muscles, or brow are injected at the same surgery, the procedure is considered to be unilateral. Bilateral procedures will only be considered when both eyes or both sides of the face are injected.

Achalasia

Botulinum toxin for achalasia may be considered for the patient who has not responded satisfactorily to conventional therapy; is at high risk of complication from pneumatic dilation or surgical myotomy; has had treatment failure with pneumatic dilation or surgical myotomy; had perforation from pneumatic dilation; has an epiphrenic diverticulum or hiatal hernia; or has esophageal varices.

Anal Fissure

Botulinum toxin for chronic anal fissure may be considered for the patient who has not responded satisfactorily to conventional therapy.

Hyperhidrosis

OnabotulinumtoxinA has been approved by the Federal Drug Administration (FDA) for treatment of severe primary axillary hyperhidrosis (primary focal hyperhidrosis) that is inadequately managed with topical therapy. Compendia list onabotulinumtoxinA and rimabotulinumtoxinB as acceptable off-label agents for this condition. The definition of primary focal hyperhidrosis is severe sweating, beyond physiological needs; focal, visible, severe sweating of at least six (6) months duration without apparent cause with at least two (2) of the following characteristics: bilateral and relatively symmetric, significant impairment in daily activities, age of onset less than 25 years, positive family history, and cessation of focal sweating during sleep.

Sialorrhea

The treatment of sialorrhea due to conditions such as motor neuron disease or Parkinson's disease in those patients who have failed to respond to a reasonable trial of traditional therapies (eg., anticholinergics and speech therapy) or who have a contraindication to or cannot tolerate anticholinergic therapy, will be allowed for coverage.

Urinary Incontinence

Urinary incontinence due to neurogenic detrusor overactivity (NDO) commonly occurs in patients with spinal cord injuries (SCI) or neurological diseases such as multiple sclerosis (MS). Patients with NDO usually use clean intermittent self-catheterization (CIC) to empty the bladder. When incontinence episodes occur between catheterizations, oral anticholinergic agents are used to decrease bladder contractility and improve incontinence.

Headache/Migraine

Coverage will only be allowed for those patients chronic daily headaches (headache disorders occurring greater than 15 days a month - in many cases daily with a duration of four or more hours - for a period of at least 3 months) who have significant disability due to the headaches, and have been refractory to standard and usual conventional therapy. The etiology of the chronic daily headache may be chronic tension-type headache or chronic migraine (CM). CM is characterized by headache on > 15 days per month, of which at least 8 headache days per month meet criteria for migraine without aura or respond to migraine-specific treatment. For continuing Botulism toxin therapy the patients must demonstrate a significant decrease in the number and frequency of headaches and an improvement in function upon receiving Botulinum toxin.

Limitations:

Medicare will allow payment for one injection per site regardless of the number of injections made into the site. A site is defined as one eye (including all muscles surrounding the eye including both upper and lower lids); one side of the face; or all muscles of one limb and their associated girdle muscles.

Failure of two definitive, consecutive, treatment sessions involving a muscle or group of muscles could preclude further coverage of the serotype used in the treatment for a period of one year after the second session. It may be reasonable, however, to attempt treatment with a different serotype.

Treatment of wrinkles using Botulinum toxins is considered to be cosmetic, and is not covered under Medicare.

Payment will not be made for any spastic condition of smooth muscle, such as spastic colon and biliary dyskinesia.

The cost of special syringes is not separately payable. They are considered part of the surgical procedure.

When the Botulinum Toxins drug is denied, the related injection code(s) will also be subject to denial.

Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

Proposed Process Information

Synopsis of Changes
Changes Fields Changed
N/A
Associated Information
Sources of Information
Bibliography
Open Meetings
Meeting Date Meeting States Meeting Information
N/A
Contractor Advisory Committee (CAC) Meetings
Meeting Date Meeting States Meeting Information
N/A
MAC Meeting Information URLs
N/A
Proposed LCD Posting Date
Comment Period Start Date
Comment Period End Date
Reason for Proposed LCD
Requestor Information
This request was MAC initiated.
Requestor Name Requestor Letter
View Letter
N/A
Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code Description
N/A

Revenue Codes

Code Description
N/A

CPT/HCPCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

Additional ICD-10 Information

General Information

Associated Information
N/A
Sources of Information
This bibliography presents those sources that were obtained during the development of this policy. CGS is not responsible for the continuing viability of Web site addresses listed below.

Allergan Pharmaceuticals Package Insert. Botox® (Botulinum Toxin Type A) Purified Neurotoxin Complex.

American Hospital Formulary System 2007. Botulinum Toxin.

American Society for Gastrointestinal Endoscopy. Guideline esophageal dilation. Gastrointestinal Endoscopy. 2006;63(6):755-760.

Aurora S. Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother. 2006;7(8)1085-1095.

Balikian RV, Zimbler MS. Primary and adjunctive uses of Botulinum toxin type A in the periorbital region. Otolaryngol Clin N Am. 2007;40:291-303.

Brashear A, Gordon MF, Dykstra DD, et.al. (1999). Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A responsive cervical dystonia. Neurology. 1999;53(7):1439-1446.

Brashear A, Gordon MF, Elovic E, et al, for the Botox Post-Stroke Spasticity Study Group. Intramuscular injection of Botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347(6):395–400.

Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with Botulinum toxin type B in upper- limb spasticity. Archives of Physical Medicine and Rehabilitation. 2003;84(1):103-107.

Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438.

Carrier Advisory Committee

Chen YH, Kuo HC. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int. 2004;73(2):156-162.

Contrarino MF, Pompili M, Tittoto P, et al. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson’s disease. Parkinsonism and Related Disorders. 2007;13:299-303.

de Seze M, Petit H, Gallien P, et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56-62.

Dodick DW, Turkel CC, DeGryse RE, et all. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache2010 American Heacache Society.

Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45(4):315-324.

Duthis J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 1007, Issue 3. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub2.

Esenyel M, Aldemir T, Gursoy E, Esenyel CZ, Demir S, Durmosoglu. Myofascial pain syndrome: Efficacy of different therapies. J Back Musculaoskeletal Rehabil. 2007;20(1):43-47.

Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo controlled study. Cephalagia. 2004;24(10)838-843.

Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic dialy headache: a five-year long experience. J Headache Pain. 206;(7)6:407-412.

Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Contantini E, Porena M. Intravesical resiniferatoxin versus botulinum_A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172(1):240-243.

Giess R, Nauman M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis. Neurol Neurosurg Psychiatry. 2000;69:121-123.

Göbel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001;91(3):195-199.

Göbel H, Heinze A, Heinze-Kuhn K, Jost WH. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol. 2001;248(Suppl 1):34-38.

Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomized double blind crossover study. Pain. 2005;118(1-2):170-175.

Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur J Pain. 2007;11(5):519-527.

Jongerius PH, van den Hoogen FJA, van Limbeek J, Gabreels FJ, van Julst K, Rotteveel JJ. Effect of Botulinum toxin in the treatment of drooling: A controlled clinical trial. Pediatrics. 2004;114:620-627.

Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo controlled study. Mov Disord. 2006 May;21(5):704-707.

Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of Botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281.

Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized double blind placebo-controlled trial. Headache. 2005:45(4):293-307.

Mertz Pharmaceuticals. XEOMIN® (incobotulinumtoxinA) FDA approval Press Release 08/02/2010.

Mertz Pharmaceuticals. XEOMIN® (incobotulinumtoxinA) Product Label.

Nauman MK, Hamm H, on behalf of the Botox Hyperhidrosis Clinical Study Group. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(15):596-599

Nauman MK, Hamm H, Lowe NJ, on behalf of the Botox Hyperhidrosis Clinical Study Group. Effect of Botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. British Journal of Dermatology. 2002;147:1218-1226.

Naik MN, Sparkar CNS, Murthy R, Honavar SG. Botulinum toxin in ophthalmic plastic surgery. Indian Journal of Ophthalmology. 2005;53:279-288.

CGS and other Medicare local coverage determinations.

Ojala T, Arokoski JPA, Partanend J. The effect of small doses of Botulinum toxin A on neck-shoulder myofascial pain syndrome: A double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22(1):90-96.

Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of Botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37-40.

Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalagia. 2004;24(1):60-65.

Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol. 2006;50(4):684-710.

Porta M. A comparative trial of Botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000;84(1-2):101-105.

Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510-515.

Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of Botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalagia. 2007;27(6):492-503.

Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with Botulinum toxin type A: a double-blind placedbo-controlled study. Headache. 2000;40(4):300-305.

Rowland L. Perspective: stroke, spasticity, and Botulinum toxin. N Engl J Med. 2002;347(6)382-383.

Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of Botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placedbo-controlled trial. Headache. 2001:41(7)658-664.

Schulte-Baukloh H, Schobert J, Stolze T, Sturzebecher B, Weiss C, Knispel HH. Efficacy of Botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006:25(2):110-115.

Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with Botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109(1-2):110-114.

Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment of neurogenic urinary incontinence: results of a single treatment randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196-200.

Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40(6):445-450.

Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized double blind, placebo controlled trial. Mayo Clin Proc. 2005;80(9):1126-1137.

Sloop RR, Cole BA, Rodolfo O. Human response to Botulinum toxin injection: type B compared with type A. Neurology. 1997;49(11)189-194.

Smuts JA, Baker MK, Smuts HM, lassen JMR, Rossouw E, Barnard PWA. Prophylactic treatment of chronic tension-type headache using Botulinum toxin type A. Eur J Neurol. 1999;6(suppl 4):S99-S102.

Turk-Gonzales M, Odderson IBR. Quantitative reduction of saliva production with Botulinum toxin type B injection into salivary glands. Neurorehabilitation and Neural Repair. 2005;19(1):58-61.

U.S Food and Drug Administration. FDA News Release 10/15/2010. FDA approves Botox to treat chronic migraine.

Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of Botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal myofascial pain syndrome. Spine. 1998;23(15):1662-1667.

Zesiewicz TA, Elble R, Louis ED, et al. American Academy of Neurology. Practice parameter: therapies for essential tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64(2-2):2008-2020.

References reviewed for 10/01/2010 publication

Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707-1714.

Simpson DM, Gracies JM Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691-1698.

Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699-1706.

References Reviewed for 11/01/2010 Reconsideration Request

BOTOX® Package Insert.

Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347(6):395-400.

Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85(7):1063-1069.

DYSPORT™ Package Insert.

MYOBLOC® Package Insert.

Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80:380-385 originally published online October 31, 2008.

U.S. Food and Drug Administration. FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist, and fingers. (March 9, 2010). http://www.fda.gove/NewsEvents/Newsroom/PressAnnouncements/ucm203776.htm.
Bibliography

N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation Reasons for Change
12/01/2022 R16

R16

Revision Effective: 12/01/2022

Revision Explanation: Annual review, no changes were made.

12/29/2022: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
11/25/2021 R15

R15

Revision Effective: 11/25/2021

Revision Explanation: Annual review, no changes were made.

11/19/2021: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
11/28/2019 R14

R14

Revision Effective: N/A

Revision Explanation: Annual review, no changes made.

11/16/2020: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
11/28/2019 R13

R13

Revision Effective: 11/28/2019

Revision Explanation: Annual review, no changes made.

11/19/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review, no changes made)
11/28/2019 R12

R12

Revision Effective: 11/28/2019

Revision Explanation: Removed other comments section from policy text and associated documentation information and placed intot he related billing and coding article.

11/19/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
09/19/2019 R11

R11

Revision Effective: 09/19/2019 Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901. For Approval, no changes.

09/13/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To Code Removal
09/19/2019 R10

R10

Revision Effective: 09/19/2019

Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901.

09/12/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To Code Removal
04/04/2019 R9

R9

Revision Effective date: 04/04/2019

Revision Explanation: All coding was removed from policy based on CR10901. New Billing and Coding article was related to policy and replaced supplemental article that was retired.

03/29/2019-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Code Migration)
10/01/2018 R8

R8

Revision Effective date: N/A

Revision Explanation: Annual review no changes

11/26/2018-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual review)
10/01/2018 R7

Revision#:R7

Revision Effective date: 10/01/2018

Revision Explanation: During the annual ICD-10 update G51.31, G51.32, G51.33 were added to group 5 and code H02.151, H02.152, H02.153, H02.154, H02.155, H02.156 were added to group 9.

09/18/2017-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To ICD-10-CM Code Changes
10/01/2015 R6

Revision#:R6
Revision Effective date: N/A
Revision Explanation: annual review no changes

11/28/2017-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (annual review)
10/01/2015 R5 Revision#:R5
Revision Effective date: N/A
Revision Explanation: annual review no changes
  • Other (Annual Review)
10/01/2015 R4 Revision#:R4
Revision Effective date:10/01/2015
Revision Explanation: Added the following ICD-10 codes to group seven for coverage: G82.20-G82.22, G83.81-g83.82, G83.89, I69.041-I69.044, and I69.049.
  • Reconsideration Request
10/01/2015 R3 Revision#:R3
Revision Effective date: N/A
Revision Explanation: annual review no changes
  • Other (Annual review)
10/01/2015 R2 Revision#:R2
Revision Effective date: 10/01/2015
Revision Explanation: Accepted 2015 HCPCs description change for 43201 and 43236.
  • Revisions Due To CPT/HCPCS Code Changes
10/01/2015 R1 Revision #: R1
Revision Effective:N/A
REvision Explanation: Third quarter HCPCS changes had code description for CPT codes 64644, 64645, and 64647.
  • Revisions Due To CPT/HCPCS Code Changes
N/A

Associated Documents

Attachments
N/A
Related Local Coverage Documents
Articles
A56472 - Billing and Coding: Botulinum Toxins
Related National Coverage Documents
N/A
Public Versions
Updated On Effective Dates Status
03/06/2024 12/07/2023 - N/A Currently in Effect View
11/29/2023 12/07/2023 - N/A Superseded View
12/29/2022 12/01/2022 - 12/06/2023 Superseded You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer